Moreover, previous findings showed that in vivo pharmacological activation of KCNQ currents with either KCNQ2-5 or KCNQ2/3 channel activators, retigabine or SF0034, respectively (Tatulian et al., 2001; Kalappa et al., 2015), prevented the development of tinnitus (Li et al., 2013; Kalappa et al., 2015). The gene discussed is KCNQ2; the disease is Tinnitus.